OUR PIPELINE & SCIENCE

We are advancing a diverse pipeline of novel small molecule candidates, each derived from a deep understanding of the molecular drivers of disease and enabled by our unique expertise in computational chemistry and drug discovery.

PROGRAMS

  • DISCOVERY
  • PRECLINICAL
  • CLINICAL
  • RIGHTS
  • PARTNERSHIP
ACC

Metabolic, Onc, Immun

Metabolic, Onc, Immun
Rights: Acquired

ACC

In May 2016, Gilead Sciences Inc. acquired Nimbus Apollo, Inc., a wholly owned subsidiary of Nimbus, and its Acetyl-CoA Carboxylase (ACC) inhibitor program for an upfront payment of $400 million. This program includes the lead candidate, NDI-010976, an allosteric ACC inhibitor, and other preclinical ACC inhibitors for the treatment of non-alcoholic steatohepatitis (NASH), and for the potential treatment of hepatocellular carcinoma (HCC) and other diseases. We have realized half of the total $1.2 billion deal value, when we subsequently received a $200 million payment in November 2016 – the first of several potential additional development-related payments that could total up to $800 million. Gilead is responsible for development and commercialization of our original molecule and other ACC inhibitors.

Acquired
CLINICAL
Undisclosed

Broad-spectrum fungicides

Broad-spectrum fungicides
Rights: Partnered

Undisclosed (Anti-fungal)

We work in collaboration with Monsanto to develop broad-spectrum fungicides with new modes of action to help farmers control diseases and promote overall plant health. With Monsanto, we created a jointly owned entity in 2013, which uses access to Nimbus' validated computational platform to develop new fungicides.

Partnered
CLINICAL
IRAK4

Immunology, Oncology

Immunology, Oncology
Rights: Partnered

IRAK4

In October 2015, we announced an exclusive worldwide license agreement with Genentech, a member of the Roche Group, to discover and develop small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4). Genentech is responsible for all preclinical and clinical development, manufacturing and commercialization.

Partnered
PRECLINICAL
TYK2

Autoimmune, Oncology

Autoimmune, Oncology
Rights: Partnered

TYK2

In October 2017, Nimbus and Celgene entered a long-term strategic immunology alliance, which includes Nimbus’ tyrosine kinase 2 (Tyk2) program. Tyk2 is a high-potential target for the treatment of autoimmune disorders including rheumatoid arthritis, lupus, Crohn’s disease, psoriasis and multiple sclerosis. Under the terms of the agreement, Nimbus received an upfront payment and is eligible for potential downstream milestone payments if Celgene chooses to exercise its option to acquire the Tyk2 program. Nimbus will retain full control of research and development activities for the Tyk2 program prior to the program’s option point.

Partnered
PRECLINICAL
Sting Antagonist

Autoimmune

Autoimmune
Rights: Partnered

STING antagonist

In October 2017, Nimbus and Celgene entered a long-term strategic immunology alliance, which includes Nimbus’ preclinical stimulator of interferon genes (STING) antagonist program. This program seeks to block the role played by STING in the activation of the innate immune system in lupus and other interferonopathies. Under the terms of the agreement, Nimbus received an upfront payment and is eligible for potential downstream milestone payments if Celgene chooses to exercise its option to acquire the STING antagonist program. Nimbus will retain full control of research and development activities for the STING antagonist program prior to the program’s option point. Nimbus will continue to own and develop its small-molecule STING agonist program for immuno-oncology, which is not part of the agreement with Celgene.

Partnered
DISCOVERY
Sting Agonist

Immuno-oncology

Immuno-oncology
Rights: Wholly Owned

Wholly Owned
DISCOVERY
others

Undisclosed (Meta, Onc, Immun)

Undisclosed (Meta, Onc, Immun)
Rights: Wholly Owned

Wholly Owned
DISCOVERY
ACC

In May 2016, Gilead Sciences Inc. acquired Nimbus Apollo, Inc., a wholly owned subsidiary of Nimbus, and its Acetyl-CoA Carboxylase (ACC) inhibitor program for an upfront payment of $400 million. This program includes the lead candidate, NDI-010976, an allosteric ACC inhibitor, and other preclinical ACC inhibitors for the treatment of non-alcoholic steatohepatitis (NASH), and for the potential treatment of hepatocellular carcinoma (HCC) and other diseases. We have realized half of the total $1.2 billion deal value, when we subsequently received a $200 million payment in November 2016 – the first of several potential additional development-related payments that could total up to $800 million. Gilead is responsible for development and commercialization of our original molecule and other ACC inhibitors.

IRAK4

In October 2015, we announced an exclusive worldwide license agreement with Genentech, a member of the Roche Group, to discover and develop small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4). Genentech is responsible for all preclinical and clinical development, manufacturing and commercialization.

Undisclosed (Anti-fungal)

We work in collaboration with Monsanto to develop broad-spectrum fungicides with new modes of action to help farmers control diseases and promote overall plant health. With Monsanto, we created a jointly owned entity in 2013, which uses access to Nimbus’ validated computational platform to develop new fungicides.

Tyk2

In October 2017, Nimbus and Celgene entered a long-term strategic immunology alliance, which includes Nimbus’ tyrosine kinase 2 (Tyk2) program. Tyk2 is a high-potential target for the treatment of autoimmune disorders including rheumatoid arthritis, lupus, Crohn’s disease, psoriasis and multiple sclerosis. Under the terms of the agreement, Nimbus received an upfront payment and is eligible for potential downstream milestone payments if Celgene chooses to exercise its option to acquire the Tyk2 program. Nimbus will retain full control of research and development activities for the Tyk2 program prior to the program’s option point.

STING antagonist

In October 2017, Nimbus and Celgene entered a long-term strategic immunology alliance, which includes Nimbus’ preclinical stimulator of interferon genes (STING) antagonist program. This program seeks to block the role played by STING in the activation of the innate immune system in lupus and other interferonopathies. Under the terms of the agreement, Nimbus received an upfront payment and is eligible for potential downstream milestone payments if Celgene chooses to exercise its option to acquire the STING antagonist program. Nimbus will retain full control of research and development activities for the STING antagonist program prior to the program’s option point. Nimbus will continue to own and develop its small-molecule STING agonist program for immuno-oncology, which is not part of the agreement with Celgene.

Publications & Abstracts

Publications
posters & abstracts

location

130 Prospect Street, Suite 301
Cambridge, MA 02139
USA

call US

857-999-2009